This prognostic study projects U.S. demand for primary and revision total joint replacement specifically among patients under 65 years old, from 2010 to 2030. Using Nationwide Inpatient Sample data from 1993-2006 and Poisson regression, the authors ask whether young patients will become the majority of TJR recipients and when that crossover will occur.
Joint replacement was conceived by Charnley as a procedure for low-activity elderly patients. This paper shows the demographic center of gravity has shifted: by 2006, nearly half of all TJR recipients were already under 65, and the trajectory pointed toward young patients becoming the majority for most procedure types.
When you are selecting an implant for a 52-year-old with end-stage knee arthritis, this paper is the quantitative backdrop. The explosive growth in the 45-54 cohort (17-fold projected increase for primary TKA by 2030) is why implant longevity, bearing surface selection, and revision-friendliness matter so much in that age group.
The divergence between the variable-rate and constant-rate models is a useful concept for boards and policy discussions: if surgical rates plateau, the burden is manageable; if historical growth continues, the system faces a dramatic capacity and cost challenge.
The authors explicitly note the United States lacks a national TJR registry — unlike Sweden, which credits its registry with reducing revision burden. This gap limits our ability to track long-term implant performance across age groups, which is especially consequential for the growing young-patient population.
This prognostic study projects U.S. demand for primary and revision total joint replacement specifically among patients under 65 years old, from 2010 to 2030. Using Nationwide Inpatient Sample data from 1993-2006 and Poisson regression, the authors ask whether young patients will become the majority of TJR recipients and when that crossover will occur.
Joint replacement was conceived by Charnley as a procedure for low-activity elderly patients. This paper shows the demographic center of gravity has shifted: by 2006, nearly half of all TJR recipients were already under 65, and the trajectory pointed toward young patients becoming the majority for most procedure types.
When you are selecting an implant for a 52-year-old with end-stage knee arthritis, this paper is the quantitative backdrop. The explosive growth in the 45-54 cohort (17-fold projected increase for primary TKA by 2030) is why implant longevity, bearing surface selection, and revision-friendliness matter so much in that age group.
The divergence between the variable-rate and constant-rate models is a useful concept for boards and policy discussions: if surgical rates plateau, the burden is manageable; if historical growth continues, the system faces a dramatic capacity and cost challenge.
The authors explicitly note the United States lacks a national TJR registry — unlike Sweden, which credits its registry with reducing revision burden. This gap limits our ability to track long-term implant performance across age groups, which is especially consequential for the growing young-patient population.